4.31
前日終値:
$4.20
開ける:
$4.16
24時間の取引高:
800.43K
Relative Volume:
0.67
時価総額:
$828.92M
収益:
$12.99M
当期純損益:
$-74.39M
株価収益率:
-9.7955
EPS:
-0.44
ネットキャッシュフロー:
$-78.92M
1週間 パフォーマンス:
-4.65%
1か月 パフォーマンス:
-3.79%
6か月 パフォーマンス:
+35.96%
1年 パフォーマンス:
+24.57%
Arbutus Biopharma Corp Stock (ABUS) Company Profile
名前
Arbutus Biopharma Corp
セクター
電話
604-419-3200
住所
701 VETERANS CIRCLE, WARMINSTER, PA
ABUS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
ABUS
Arbutus Biopharma Corp
|
4.31 | 807.76M | 12.99M | -74.39M | -78.92M | -0.44 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Arbutus Biopharma Corp Stock (ABUS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2022-02-02 | アップグレード | Jefferies | Hold → Buy |
| 2021-02-25 | 開始されました | Jefferies | Hold |
| 2020-12-17 | 開始されました | H.C. Wainwright | Buy |
| 2020-07-27 | 再開されました | JMP Securities | Mkt Outperform |
| 2020-07-24 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2020-05-19 | アップグレード | Wedbush | Neutral → Outperform |
| 2020-03-06 | アップグレード | Chardan Capital Markets | Neutral → Buy |
| 2020-02-20 | 開始されました | Robert W. Baird | Outperform |
| 2020-02-05 | アップグレード | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-10-07 | 繰り返されました | B. Riley FBR | Buy |
| 2019-10-04 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2018-10-16 | アップグレード | B. Riley FBR | Neutral → Buy |
| 2018-10-15 | アップグレード | Wedbush | Underperform → Neutral |
| 2018-10-12 | 繰り返されました | Chardan Capital Markets | Buy |
| 2018-07-06 | ダウングレード | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-03-19 | 再開されました | Chardan Capital Markets | Buy |
| 2018-03-19 | ダウングレード | Wedbush | Outperform → Neutral |
| 2018-01-05 | 開始されました | B. Riley FBR, Inc. | Buy |
| 2017-04-04 | アップグレード | Chardan Capital Markets | Neutral → Buy |
| 2017-02-01 | 繰り返されました | Wedbush | Outperform |
| 2016-12-13 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2016-11-30 | アップグレード | Chardan Capital Markets | Neutral → Buy |
すべてを表示
Arbutus Biopharma Corp (ABUS) 最新ニュース
How Arbutus Biopharma Corporation (I9DN) stock reacts to new regulationsEarnings Risk Summary & Weekly Setup with High ROI Potential - newser.com
A look into Arbutus Biopharma Corp (ABUS)’s deeper side - Setenews
Why Arbutus Biopharma Corporation stock is trending among retail tradersJuly 2025 Volume & Daily Growth Stock Tips - newser.com
Arbutus Reports Major Advances in HBV Candidate as Litigation Against Moderna, Pfizer Builds Toward Trial - MyChesCo
How Arbutus Biopharma Corporation (I9DN) stock trades after earningsJuly 2025 Closing Moves & Low Risk Investment Opportunities - newser.com
Arbutus Biopharma Corporation stock trend outlook and recovery pathQuarterly Market Summary & Daily Price Action Insights - newser.com
Can Arbutus Biopharma Corporation (I9DN) stock hold up in economic slowdownMarket Performance Report & Free Safe Entry Trade Signal Reports - newser.com
How Arbutus Biopharma Corporation (I9DN) stock compares with market leadersWeekly Trade Analysis & Growth Oriented Trading Recommendations - newser.com
How Arbutus Biopharma Corporation stock compares to growth peersMarket Risk Analysis & Fast Moving Trade Plans - newser.com
Arbutus Biopharma’s (ABUS) Buy Rating Reiterated at Chardan Capital - Defense World
Quantitative breakdown of Arbutus Biopharma Corporation recent move2025 Big Picture & Reliable Intraday Trade Plans - newser.com
What indicators show strength in Arbutus Biopharma Corporation2025 Investor Takeaways & Low Volatility Stock Recommendations - newser.com
What analysts say about Arbutus Biopharma Corporation I9DN stockBull Market Opportunities & Follow Top Performers in the Community - earlytimes.in
Arbutus Biopharma (ABUS) Receives Steady Buy Rating from Chardan Capital | ABUS Stock News - GuruFocus
Arbutus: Q3 Earnings Snapshot - New Haven Register
Arbutus Biopharma earnings missed, revenue fell short of estimates By Investing.com - Investing.com South Africa
Arbutus Biopharma shares rise as imdusiran data shows promising results By Investing.com - Investing.com Canada
Arbutus Biopharma shares rise as imdusiran data shows promising results - Investing.com
Arbutus Biopharma earnings missed, revenue fell short of estimates - Investing.com
Arbutus Biopharma Faces Losses And Legal Battles This Quarter - Finimize
Arbutus (ABUS) Reports Q3 Results, Highlights Promising Imdusira - GuruFocus
Nothing is Better Than Arbutus Biopharma Corp (ABUS) stock at the moment - Setenews
Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update - The Manila Times
Arbutus Biopharma Corp SEC 10-Q Report - TradingView
Is Arbutus Biopharma Corporation (I9DN) stock a buy for dividend portfoliosQuarterly Profit Review & Technical Pattern Based Signals - newser.com
Signal strength of Arbutus Biopharma Corporation stock in tech scannersJuly 2025 Reactions & Safe Capital Growth Plans - newser.com
Intraday pattern recognizer results for Arbutus Biopharma CorporationMarket Activity Summary & Real-Time Volume Analysis Alerts - newser.com
Can Arbutus Biopharma Corporation stock sustain revenue growthNew Guidance & Low Risk Entry Point Tips - newser.com
How does Arbutus Biopharma Corp (ABUS) change from a tortoise to a hare? - setenews.com
Will Arbutus Biopharma Corporation (I9DN) stock see insider accumulationWeekly Trend Summary & Technical Entry and Exit Alerts - newser.com
Arbutus Biopharma Corp (ABUS) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):